Takeda

For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation. Today, our organization spans the globe—colleagues across business units and functions face challenges head-on to deliver life-transforming treatments, guided by our commitment to patients, our people and the planet.

As a values-based, R&D-driven biopharmaceutical leader headquartered in Japan, we focus our R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. In addition to our R&D efforts, we’re laser-focused on harnessing the power of data, digital, and technology to improve health outcomes for patients across the globe.

Since our founding in Japan, integrity and putting patients first have been at the heart of our identity. We’re proud of our employees and their commitment to improving the quality of life for patients, and to working with our partners in health care in approximately 80 countries and regions. With each new breakthrough comes opportunities to develop your career, hone new skills, and create a brighter future.

For more information, visit https://jobs.takeda.com/

650 East Kendall Street Cambridge MA 02421 US
  • Featured Employer Badge
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • Takeda Top Global Employer 2024
  • Takeda LinkedIn Top 2024.png
  • 2025BPTW_GeneralBadge_FullColor.png
  • Takeda Disability Equality 2024
  • Takeda BGH 2024.png
CULTURE

At Takeda, we share a vision for the future where health care is more accessible, inclusive, sustainable, and affordable for all. And we believe our people are our greatest promise for delivering it. Individually, from R&D to IT, Finance to Maintenance, and every department in between, each of us brings the expertise, dedication, passion, and courage it takes to make history every day and change health care forever.

We’re grounded in over 240 years of history and are inspired each and every day by the possibility our future holds. Since our founding in Japan in 1781, integrity and putting patients first have been at the heart of our identity. These principles are ingrained in our culture and inspire our vision for the future. Our founding values remain core to our culture today and will inspire ideas that help you create a better tomorrow.

Across all parts of the business and corners of the world, our values unite and guide us. Our values are more than words on a page. They guide everything we do, uniting our teams across the world and lead us into the future. Our teams span the globe and work across a broad range of therapeutic areas, but we are connected by a shared values system. Bring your collaborative mindset and commitment and help us deliver the vision.

We’re dedicated to patients, our people, and the planet and proud of the contributions made by all our employees to drive impact. Each person’s contributions help us do better for patients, our fellow colleagues, and the planet. Take pride in knowing you help create a brighter future for patients, people, and the planet.

We’re constantly evolving—acting with endurance in our steadfast pursuit to achieve the best outcomes for our patients. We’re future-focused, delivering life-changing treatments through innovation. The drive to do better for patients means we are continuously evolving as a company and within our individual roles. Pursue new possibilities for patients while discovering new opportunities to grow your career.

DIVERSITY, EQUITY & INCLUSION

Across Takeda, we embrace and celebrate diversity, while striving to give patients and our people equitable access to opportunities that help them achieve their full potential. We take a values-based approach to inclusive patient experiences, inclusive work environments, workforce diversity and sustainable societal impact. We believe that diverse perspectives and experiences are key drivers of innovation. This starts with fostering an environment that creates a sense of belonging, allowing not only for everyone to have a voice, but a voice that is heard and valued.

NEWS
Seattle Genetics and Takeda show off the impressive survival data that prompted the FDA to give approval to Adcetris for this indication.
There are 7 billion people in the world. Of those, 5 billion have access to life-saving medications, while 2 billion do not. That is a gap that pharmaceutical companies can help close through increased R&D programs, logistical initiatives and the lowering of prices, the Access to Medicine Foundation announced Tuesday.
After announcing a potential snag with the European Commission last month, Takeda said this morning that it received clearance for its acquisition of Shire. The clearance is conditional on addressing overlaps in the companies’ inflammatory bowel disease businesses.
Crescendo Biologics Ltd today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.
Pharma giant Takeda Pharmaceutical is looking to begin 2019 with a bang – closing its $62 billion acquisition of Shire plc by Jan. 8. This morning Takeda announced that it will hold an investor vote next month on the planned acquisition in order to swiftly move and finalize the deal.
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
FDA
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
Acting on an option out of 2016 collaboration deal, Japan’s Takeda Pharmaceutical licensed Humabodies directed to one of its oncology targets from Cambridge, UK’s Crescendo Biologics.
JOBS
IN THE PRESS